

Stefano Fanti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7892435/publications.pdf>

Version: 2024-02-01

343
papers

19,403
citations

10389

72
h-index

14208

128
g-index

356
all docs

356
docs citations

356
times ranked

14021
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence. <i>European Urology Oncology</i> , 2023, 6, 41-48. | 5.4 | 14 |
| 2 | Single-photon cardiac imaging in patients with cardiac implantable electrical devices. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 633-641. | 2.1 | 4 |
| 3 | Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 1566-1575. | 2.1 | 7 |
| 4 | Coronavirus (COVID-19) pandemic mediated changing trends in nuclear medicine education and training: time to change and scintillate. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 427-435. | 6.4 | 10 |
| 5 | Diagnostic Performance and Clinical Impact of ⁶⁸ Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study). <i>Journal of Nuclear Medicine</i> , 2022, 63, 240-247. | 5.0 | 28 |
| 6 | The Impact of COVID-19 on Nuclear Medicine in Europe. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 17-24. | 4.6 | 5 |
| 7 | Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. <i>Journal of Nuclear Medicine</i> , 2022, 63, 59-68. | 5.0 | 61 |
| 8 | New Biomarkers With Prognostic Impact Based on Multitracer PET/CT Imaging in Neuroendocrine Neoplasms. <i>Clinical Nuclear Medicine</i> , 2022, 47, 219-220. | 1.3 | 9 |
| 9 | Facts and Myths About Stage Migration: Should the Will Rogers Phenomenon Ride off into the Distance?. <i>European Urology Oncology</i> , 2022, , . | 5.4 | 1 |
| 10 | PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What's Now, What's New, and What's Coming?. <i>Cancers</i> , 2022, 14, 907. | 3.7 | 8 |
| 11 | Ten-year follow-up of cardiac resynchronization therapy patients with non-ischemic dilated cardiomyopathy assessed by radionuclide angiography: a single-center cohort study. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, , . | 1.3 | 0 |
| 12 | Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors. <i>Cancers</i> , 2022, 14, 1055. | 3.7 | 17 |
| 13 | Two birds with one stone: can [68Ga]Ga-DOTANOC PET/CT image quality be improved through BMI-adjusted injected activity without increasing acquisition times?. <i>British Journal of Radiology</i> , 2022, 95, 20211152. | 2.2 | 0 |
| 14 | [68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2022, 5, 273-282. | 5.4 | 37 |
| 15 | Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study. <i>Cancers</i> , 2022, 14, 1744. | 3.7 | 7 |
| 16 | New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms. <i>Current Treatment Options in Oncology</i> , 2022, 23, 703-720. | 3.0 | 20 |
| 17 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141. | 1.9 | 51 |
| 18 | The role of prostate-specific membrane antigen PET/computed tomography in the management of prostate cancer patients: could we ask for more?. <i>Current Opinion in Urology</i> , 2022, 32, 269-276. | 1.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | A novel tool for motion-related dose inaccuracies reduction in 99mTc-MAA SPECT/CT images for SIRT planning. <i>Physica Medica</i> , 2022, 98, 98-112. | 0.7 | 4 |
| 20 | Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 1015-1024. | 0.8 | 18 |
| 21 | Effects of Radiation Therapy and Chemotherapy on the Musculoskeletal System. <i>Seminars in Musculoskeletal Radiology</i> , 2022, 26, 338-353. | 0.7 | 2 |
| 22 | EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([¹⁷⁷ Lu]Lu-PSMA). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3328-3329. | 6.4 | 1 |
| 23 | Prediction of Overall Survival in Cervical Cancer Patients Using PET/CT Radiomic Features. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 5946. | 2.5 | 4 |
| 24 | EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [¹⁷⁷ Lu]Lu-PSMA Radioligand Therapy. <i>European Urology Oncology</i> , 2022, 5, 530-536. | 5.4 | 20 |
| 25 | Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 469-476. | 6.4 | 119 |
| 26 | Long-Term Metabolic Assessment of Cryopreserved Sternal Allograft: A Case Series. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1059-1063. | 1.3 | 1 |
| 27 | Standardization of ¹⁸ F-FDG PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 116-125. | 1.6 | 85 |
| 28 | EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer 2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2021, 79, 243-262. | 1.9 | 1,545 |
| 29 | EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II 2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 263-282. | 1.9 | 633 |
| 30 | The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2021, 4, 370-395. | 5.4 | 25 |
| 31 | Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 675-678. | 5.0 | 16 |
| 32 | ¹⁸ F-Choline, ⁶⁸ Ga-PSMA-11 and ¹⁸ F-FDG PET/CT in Treatment Response Evaluation: Prostate Cancer. , 2021, , 261-295. | | 0 |
| 33 | PET Imaging in Neuro-Endocrine Neoplasms (NEN). , 2021, , . | | 0 |
| 34 | E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1626-1638. | 6.4 | 188 |
| 35 | Comments to Survey by the ANSM of the imaging protocol, detection rate, and safety of ⁶⁸ Ga-PSMA-11 PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2690-2691. | 6.4 | 3 |
| 36 | Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 596-604. | 5.0 | 79 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. <i>European Urology Oncology</i> , 2021, 4, 714-730. | 5.4 | 16 |
| 38 | Androgen deprivation therapy and its modulation of PSMA expression in prostate cancer: mini review and case series of patients studied with sequential [68Ga]-Ga-PSMA-11 PET/CT. <i>Clinical and Translational Imaging</i> , 2021, 9, 215-220. | 2.1 | 5 |
| 39 | Prostate specific membrane antigen positron emission tomography/computed tomography and staging high risk prostate cancer: a non-systematic review of high clinical impact literature. <i>Minerva Urology and Nephrology</i> , 2021, 73, 32-41. | 2.5 | 5 |
| 40 | Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. <i>European Journal of Cancer</i> , 2021, 146, 56-73. | 2.8 | 120 |
| 41 | The Role of [18F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [11C]Choline PET/CT and Histopathological Analysis. <i>Cancers</i> , 2021, 13, 1575. | 3.7 | 4 |
| 42 | Calcification as a cause of potential false-positive findings in bone scintigraphy verified with [68Ga]Ga-PSMA-11 PET/CT - a case report. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 473-475. | 0.4 | 0 |
| 43 | Impact of 18F-FDG PET/CT, CT and EBUS/TBNA on preoperative mediastinal nodal staging of NSCLC. <i>BMC Medical Imaging</i> , 2021, 21, 49. | 2.7 | 13 |
| 44 | Off-Label Use of Letermovir as Preemptive Anti-Cytomegalovirus Therapy in a Pediatric Allogeneic Peripheral Blood Stem Cell Transplant. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 1185-1190. | 2.7 | 16 |
| 45 | Overview and recent advances in PET/CT imaging in lymphoma and multiple myeloma. <i>European Journal of Radiology</i> , 2021, 141, 109793. | 2.6 | 16 |
| 46 | A [68Ga]Ga-DOTANOC PET/CT Radiomic Model for Non-Invasive Prediction of Tumour Grade in Pancreatic Neuroendocrine Tumours. <i>Diagnostics</i> , 2021, 11, 870. | 2.6 | 13 |
| 47 | Contemporary Imaging Technologies for Men with Rising Prostate-specific Antigen After Radical Prostatectomy and Before Early Salvage Irradiation: Where Do We Stand?. <i>European Urology Oncology</i> , 2021, 4, 356-357. | 5.4 | 2 |
| 48 | Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications. <i>Clinical and Translational Imaging</i> , 2021, 9, 423-438. | 2.1 | 3 |
| 49 | Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab. <i>European Journal of Cancer</i> , 2021, 150, 99-107. | 2.8 | 36 |
| 50 | [18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 390-409. | 6.4 | 7 |
| 51 | Salvage therapy for prostate cancer after radical prostatectomy. <i>Nature Reviews Urology</i> , 2021, 18, 643-668. | 3.8 | 26 |
| 52 | Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC). <i>Diagnostics</i> , 2021, 11, 1430. | 2.6 | 7 |
| 53 | Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience. <i>Cancers</i> , 2021, 13, 4789. | 3.7 | 18 |
| 54 | Theranostics in oncology: What radiologists want to know. <i>European Journal of Radiology</i> , 2021, 142, 109875. | 2.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Prostate cancer: Molecular imaging and MRI. <i>European Journal of Radiology</i> , 2021, 143, 109893. | 2.6 | 6 |
| 56 | PET/CT Variants and Pitfalls in Prostate Cancer: What You Might See on PET and Should Never Forget. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 621-632. | 4.6 | 17 |
| 57 | ⁶⁸ Ga-Prostate-specific membrane antigen (PSMA) positron emission tomography (pet) in prostate cancer: a systematic review and meta-analysis. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2021, 47, 705-729. | 1.5 | 11 |
| 58 | Radiological and Nuclear Medicine Imaging of Multiple Myeloma. , 2021, , . | | 0 |
| 59 | Can Q.Clear reconstruction be used to improve [⁶⁸ Ga]Ga-DOTANOC PET/CT image quality in overweight NEN patients?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, , 1. | 6.4 | 10 |
| 60 | PET/CT-Guided Biopsy of Suspected Lung Lesions Requires Less Rebiopsy Than CT-Guided Biopsy Due to Inconclusive Results. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1057-1061. | 5.0 | 10 |
| 61 | Lung uptake detected by Ga-PSMA-11 PET/CT in prostate cancer patients with SARS-CoV-2: a case series. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 300-306. | 1.0 | 3 |
| 62 | The Role of FDG-PET and Whole-Body MRI in High Grade Bone Sarcomas With Particular Focus on Osteosarcoma. <i>Seminars in Nuclear Medicine</i> , 2021, , . | 4.6 | 6 |
| 63 | Evaluation of an Automated Module Synthesis and a Sterile Cold Kit-Based Preparation of ⁶⁸ Ga-PSMA-11 in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 716-722. | 5.0 | 20 |
| 64 | Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. <i>European Urology Focus</i> , 2020, 6, 231-234. | 3.1 | 131 |
| 65 | Prediction nomogram for ⁶⁸ Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 136-146. | 6.4 | 56 |
| 66 | FDG-PET assessment and metabolic patterns in Lafora disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1576-1584. | 6.4 | 12 |
| 67 | Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria. <i>Journal of Nuclear Medicine</i> , 2020, 61, 678-682. | 5.0 | 81 |
| 68 | Promise of PET imaging in prostate cancer. <i>Current Opinion in Urology</i> , 2020, 30, 9-16. | 1.8 | 2 |
| 69 | Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1037-1042. | 5.0 | 19 |
| 70 | [¹⁸ F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging—version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 579-591. | 6.4 | 39 |
| 71 | EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250. | 1.9 | 132 |
| 72 | Combined Visual and Semiquantitative Evaluation Improves Outcome Prediction by Early Midtreatment ¹⁸ F-FDG PET in Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2020, 61, 999-1005. | 5.0 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | The Role of Ultrasound in the Diagnosis of Soft Tissue Tumors. <i>Seminars in Musculoskeletal Radiology</i> , 2020, 24, 135-155. | 0.7 | 10 |
| 74 | Global Impact of COVID-19 on Nuclear Medicine Departments: An International Survey in April 2020. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1278-1283. | 5.0 | 51 |
| 75 | PET imaging in urology. <i>Current Opinion in Urology</i> , 2020, Publish Ahead of Print, 623-627. | 1.8 | 11 |
| 76 | Optical coherence tomography assessment of macrophages accumulation in non-ST-segment elevation acute coronary syndromes. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 860-865. | 1.5 | 4 |
| 77 | Reply to "No time like the present: time to rethink our habits in science and continuous medical education?" <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1630-1631. | 6.4 | 0 |
| 78 | Diagnostic Accuracy of Cardiac Computed Tomography and 18-F Fluorodeoxyglucose Positron Emission Tomography in Cardiac Masses. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2400-2411. | 5.3 | 40 |
| 79 | Potential use of radiolabelled neurotensin in PET imaging and therapy of patients with pancreatic cancer. <i>Nuclear Medicine Communications</i> , 2020, 41, 411-415. | 1.1 | 6 |
| 80 | Predictive Role of MRI and 18F FDG PET Response to Concurrent Chemoradiation in T2b Cervical Cancer on Clinical Outcome: A Retrospective Single Center Study. <i>Cancers</i> , 2020, 12, 659. | 3.7 | 8 |
| 81 | Identification of a Patient Cohort with Relapsing Diffuse Large B-Cell Lymphoma with a Low International Prognostic Index in PET/CT Using a 2-Gene (LMO2/TNFRSF9) Scoring System. <i>Acta Haematologica</i> , 2020, 143, 600-602. | 1.4 | 0 |
| 82 | Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. <i>European Urology</i> , 2020, 77, 614-627. | 1.9 | 101 |
| 83 | Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3058-3065. | 6.4 | 8 |
| 84 | What Is the Role of Imaging in Cancers?. <i>Cancers</i> , 2020, 12, 1494. | 3.7 | 1 |
| 85 | Prostate-specific Membrane Antigen Positron Emission Tomography Scans Before Curative Treatment: Ready for Prime Time?. <i>European Urology</i> , 2020, 78, e125-e128. | 1.9 | 3 |
| 86 | Radioguided surgery with 68Ga-DOTATATE for patients with neuroendocrine tumors. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 67-69. | 1.5 | 3 |
| 87 | Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1963-1996. | 1.6 | 107 |
| 88 | Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547. | 1.9 | 278 |
| 89 | Predictive accuracy and clinical benefit of a nomogram aimed to predict 68Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSA $\leq 1\text{ ng/ml}$ external validation on a single institution database. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2100-2105. | 6.4 | 20 |
| 90 | Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. <i>Journal of Nuclear Medicine</i> , 2020, 61, 552-562. | 5.0 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences. <i>Journal of Nuclear Medicine</i> , 2020, 61, 626-629. | 5.0 | 65 |
| 92 | Clinical aspects of mCRPC management in patients treated with radium-223. <i>Scientific Reports</i> , 2020, 10, 6681. | 3.3 | 11 |
| 93 | Non-FDG PET/CT. <i>Recent Results in Cancer Research</i> , 2020, 216, 669-718. | 1.8 | 9 |
| 94 | [18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. <i>EJNMMI Research</i> , 2020, 10, 122. | 2.5 | 8 |
| 95 | Alternative and New Radiopharmaceutical Agents for Lung Cancer. <i>Current Radiopharmaceuticals</i> , 2020, 13, 185-194. | 0.8 | 11 |
| 96 | T Staging and Target Volume Definition by Imaging in GU Tumors. <i>Medical Radiology</i> , 2020, , 221-254. | 0.1 | 0 |
| 97 | Negative 11C-choline PET/computed tomography imaging in restaging of patients with prostate cancer with serum prostate-specific antigen values >20â€‰%ng/mL. <i>Nuclear Medicine Communications</i> , 2020, 41, 1178-1182. | 1.1 | 0 |
| 98 | The Philosophy of Advanced Medical Imaging: Mapping the Field. <i>SpringerBriefs in Ethics</i> , 2020, , 1-9. | 0.6 | 0 |
| 99 | 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5Âng/ml. Efficacy and impact on treatment strategy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 11-19. | 6.4 | 96 |
| 100 | EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2536-2544. | 6.4 | 265 |
| 101 | Response to Prof. Ingo Brink and Prof. Aubalewska-Dydejczyk regarding Their "Letter to the Editor". <i>Neuroendocrinology</i> , 2019, 108, 366-366. | 2.5 | 0 |
| 102 | Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. <i>Radiology</i> , 2019, 292, 273-286. | 7.3 | 46 |
| 103 | Reliability of molecular imaging diagnostics. <i>Synthese</i> , 2019, , 1. | 1.1 | 7 |
| 104 | EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). <i>European Urology</i> , 2019, 76, 790-813. | 1.9 | 151 |
| 105 | Multi-Imaging Investigation to Evaluate the Relationship between Serum Cystatin C and Features of Atherosclerosis in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Applied Sciences (Switzerland)</i> , 2019, 9, 657. | 2.5 | 0 |
| 106 | Male Breast Cancer Detected by 68Ga-PSMA-11 PET/CT in a Patient With Prostate Cancer With Pelvic Lymph Node Metastasis. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 154-156. | 1.9 | 9 |
| 107 | 18F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis" A Multicenter Retrospective Study. <i>Cancers</i> , 2019, 11, 700. | 3.7 | 23 |
| 108 | Potential Prognostic Role of 18F-FDG PET/CT in Invasive Epithelial Ovarian Cancer Relapse. A Preliminary Study. <i>Cancers</i> , 2019, 11, 713. | 3.7 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | How does ⁶⁸ Ga prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?. <i>International Journal of Urology</i> , 2019, 26, 804-811. | 1.0 | 21 |
| 110 | The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 321-330. | 3.8 | 33 |
| 111 | Molecular Imaging and Theranostics—A Multidisciplinary Approach. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 247-254. | 4.6 | 19 |
| 112 | Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 2247-2254. | 1.3 | 4 |
| 113 | Use of Radium-223 Dichloride in Patients With Osteonecrosis of the Jaw Induced by Zoledronic Acid: Report of 2 Cases. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e612-e617. | 1.9 | 3 |
| 114 | ⁶⁸ Ga-DOTANOC and ¹⁸ F-DOPA PET/CT: a site-specific approach to the imaging of paragangliomas of the head and neck and of the abdomen. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1393-1393. | 6.4 | 3 |
| 115 | Novel Structured Reporting Systems for Theranostic Radiotracers. <i>Journal of Nuclear Medicine</i> , 2019, 60, 577-584. | 5.0 | 24 |
| 116 | HTA in nuclear medicine: [⁶⁸ Ga]PSMA PET/CT for patients with prostate cancer. <i>Clinical and Translational Imaging</i> , 2019, 7, 7-20. | 2.1 | 2 |
| 117 | Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFR β mutation in a metastatic GIST patient responding to imatinib. <i>Scientific Reports</i> , 2019, 9, 2172. | 3.3 | 5 |
| 118 | A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 47-76. | 5.4 | 140 |
| 119 | ⁶⁸ Ga-PSMA-11 PET accuracy in recurrent prostate cancer. <i>Translational Andrology and Urology</i> , 2019, 8, 772-774. | 1.4 | 5 |
| 120 | PSMA-PET/CT imaging in prostate cancer: why and when. <i>Clinical and Translational Imaging</i> , 2019, 7, 377-379. | 2.1 | 12 |
| 121 | Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments. <i>European Urology Oncology</i> , 2019, 2, 152-162. | 5.4 | 29 |
| 122 | Consensus Procedures in Oncological Imaging: The Case of Prostate Cancer. <i>Cancers</i> , 2019, 11, 1788. | 3.7 | 3 |
| 123 | ⁶⁸ Ga-DOTANOC PET/CT Detects Multifocal Hepatocellular Carcinoma. <i>Clinical Nuclear Medicine</i> , 2019, 44, 238-239. | 1.3 | 2 |
| 124 | Prognostic and diagnostic value of [¹⁸ F]FDG-PET/CT in restaging patients with small cell lung carcinoma. <i>Nuclear Medicine Communications</i> , 2019, 40, 808-814. | 1.1 | 8 |
| 125 | Contribution of PET imaging to mortality risk stratification in candidates to lead extraction for pacemaker or defibrillator infection: a prospective single center study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 194-205. | 6.4 | 45 |
| 126 | Single Subcutaneous Prostate Cancer Metastasis Detected by ⁶⁸ Ga-PSMA PET/CT During Early Biochemical Relapse: A Case Report. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e356-e359. | 1.9 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. <i>European Urology</i> , 2019, 75, 699-702. | 1.9 | 8 |
| 128 | Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2019, 75, 967-987. | 1.9 | 278 |
| 129 | ⁶⁸ Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 31-39. | 6.4 | 74 |
| 130 | State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer. <i>International Journal of Urology</i> , 2019, 26, 18-30. | 1.0 | 16 |
| 131 | FDG PET/CT for assessing tumour response to immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 238-250. | 6.4 | 194 |
| 132 | Highlights from 2017: impactful topics published in the <i>Annals of Nuclear Medicine</i> . <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 217-223. | 6.4 | 3 |
| 133 | Effects of cardiac resynchronization therapy on right ventricular function during rest and exercise, as assessed by radionuclide angiography, and on NT-proBNP levels. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 123-132. | 2.1 | 8 |
| 134 | Randomized Controlled Trials for Diagnostic Imaging: Conceptual and Practical Problems. <i>Topoi</i> , 2019, 38, 395-400. | 1.3 | 5 |
| 135 | Successful multidisciplinary clinical approach and molecular characterization by whole transcriptome sequencing of a cardiac myxofibrosarcoma: A case report. <i>World Journal of Clinical Cases</i> , 2019, 7, 3018-3026. | 0.8 | 7 |
| 136 | Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 7-18. | 0.7 | 19 |
| 137 | Local and Systemic Staging by Modern Imaging Modalities in Prostate Cancer. , 2019, , 125-139. | | 0 |
| 138 | Incidental Detection of Basaloid Thymic Carcinoma With ⁶⁸ Ga-PSMA-11 PET/CT in a Patient With Recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e497-e499. | 1.9 | 3 |
| 139 | Cholescintigraphic patterns in a IBS patient with postprandial diarrhea. <i>Digestive and Liver Disease</i> , 2018, 50, 720-721. | 0.9 | 0 |
| 140 | A review discussing fluciclovine (¹⁸ F) PET/CT imaging in the detection of recurrent prostate cancer. <i>Future Oncology</i> , 2018, 14, 1101-1115. | 2.4 | 8 |
| 141 | Phenotypic appearances of prostate utilizing PET-MRI and PET-CT with ⁶⁸ Ga-PSMA, radiolabelled choline and ⁶⁸ Ga-DOTATATE. <i>Nuclear Medicine Communications</i> , 2018, 39, 196-204. | 1.1 | 2 |
| 142 | Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 575-580. | 2.5 | 28 |
| 143 | Current status of theranostics in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 471-495. | 6.4 | 115 |
| 144 | Interpretation criteria for FDG PET/CT in multiple myeloma (IMPETUS): final results. IMPETUS (Italian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 712-719. | 6.4 | 95 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 145 | FDG-PET/CT Guided Biopsy in Angiosarcoma of Bone. <i>Clinical Nuclear Medicine</i> , 2018, 43, e48-e49. | 1.3 | 4 |
| 146 | Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study. <i>Abdominal Radiology</i> , 2018, 43, 2391-2399. | 2.1 | 23 |
| 147 | Pictorial essay: normal variants, lesions, and pitfalls in 68Ga-PSMA PET imaging of prostate cancer. <i>Clinical and Translational Imaging</i> , 2018, 6, 239-247. | 2.1 | 3 |
| 148 | Highlights of the 30th Annual Congress of the EANM, Vienna 2017: "Yes we can" make nuclear medicine great again. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1781-1794. | 6.4 | 9 |
| 149 | Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211. | 1.9 | 488 |
| 150 | Atlas of PET-CT. , 2018, , . | | 0 |
| 151 | Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, e696-e708. | 10.7 | 90 |
| 152 | Standardisation of PSMA images interpretation: why do we need it?. <i>Clinical and Translational Imaging</i> , 2018, 6, 331-333. | 2.1 | 4 |
| 153 | Radioguided surgery with ^{125}I radiation: a novel application with Ga68. <i>Scientific Reports</i> , 2018, 8, 16171. | 3.3 | 28 |
| 154 | 18F-FDG-PET/CT imaging in cardiac tumors: illustrative clinical cases and review of the literature. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879356. | 3.2 | 28 |
| 155 | ^{223}Ra -chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience. <i>Tumori</i> , 2018, 104, 128-136. | 1.1 | 14 |
| 156 | Prognostic value of posttreatment 18F-FDG PET/CT and predictors of metabolic response to therapy in patients with locally advanced cervical cancer treated with concomitant chemoradiation therapy: an analysis of intensity- and volume-based PET parameters. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2139-2146. | 6.4 | 38 |
| 157 | Imaging of Prostate Cancer Using ^{11}C -Choline PET/Computed Tomography. <i>Urologic Clinics of North America</i> , 2018, 45, 481-487. | 1.8 | 12 |
| 158 | Risk-related 18F-FDG PET/CT and new diagnostic strategies in patients with solitary pulmonary nodule: the ITALIAN multicenter trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1908-1914. | 6.4 | 12 |
| 159 | Delivering PET imaging results to cancer patients: steps for handling ethical issues. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2240-2241. | 6.4 | 4 |
| 160 | Preoperative Staging With ^{11}C -Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 305-312.e1. | 1.9 | 19 |
| 161 | Rapidly growing pulmonary ground-glass nodule caused by metastatic melanoma lacking uptake on 18F-FDG PET-CT. <i>Jornal Brasileiro De Pneumologia</i> , 2018, 44, 171-172. | 0.7 | 6 |
| 162 | Fluoride PET/CT in Metastatic Benign Pulmonary Calcification. <i>Nuklearmedizin - NuclearMedicine</i> , 2018, 57, N50-N51. | 0.7 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Local and Systemic Staging by Modern Imaging Modalities in Prostate Cancer. , 2018, , 1-15. | | 0 |
| 164 | Prostate cancer imaging and therapy. , 2018, , . | | 0 |
| 165 | Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET/CT?. Journal of Nuclear Cardiology, 2017, 24, 746-749. | 2.1 | 31 |
| 166 | METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. European Urology, 2017, 71, 81-92. | 1.9 | 230 |
| 167 | A Rare Case of Epididymal Metastasis After Radical Prostatectomy Detected by 68Ga-PSMA PET/CT. Clinical Genitourinary Cancer, 2017, 15, e525-e527. | 1.9 | 3 |
| 168 | The Effect of Susceptibility Artifacts Related to Metallic Implants on Adjacent-Lesion Assessment in Simultaneous TOF PET/MR. Journal of Nuclear Medicine, 2017, 58, 1167-1173. | 5.0 | 8 |
| 169 | Imaging of Prostate Cancer Using 11 C-Choline PET/Computed Tomography. PET Clinics, 2017, 12, 137-143. | 3.0 | 2 |
| 170 | The Impact of Somatostatin Receptorâ€Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. Journal of Nuclear Medicine, 2017, 58, 756-761. | 5.0 | 158 |
| 171 | 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1014-1024. | 6.4 | 589 |
| 172 | A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role?. American Journal of Roentgenology, 2017, 209, 152-158. | 2.2 | 29 |
| 173 | The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1712-1720. | 6.4 | 31 |
| 174 | Early and delayed evaluation of solid tumours with 64Cu-ATSM PET/CT. Nuclear Medicine Communications, 2017, 38, 340-346. | 1.1 | 8 |
| 175 | Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1671-1678. | 6.4 | 47 |
| 176 | Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18Fâ€DOPA. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1588-1601. | 6.4 | 319 |
| 177 | Relation between thoracic aortic inflammation and features of plaque vulnerability in the coronary tree in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. An FDG-positron emission tomography and optical coherence tomography study. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1878-1887. | 6.4 | 9 |
| 178 | Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1622-1635. | 6.4 | 91 |
| 179 | Therapy assessment in prostate cancer using choline and PSMA PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 78-83. | 6.4 | 31 |
| 180 | Comparison of CT and PET/CT for biopsy guidance in oncological patients. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1269-1274. | 6.4 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging. <i>Neuroendocrinology</i> , 2017, 105, 212-244. | 2.5 | 325 |
| 182 | New aspects of molecular imaging in prostate cancer. <i>Methods</i> , 2017, 130, 36-41. | 3.8 | 21 |
| 183 | The Wandering Mesenteric Lymph Node. <i>Clinical Nuclear Medicine</i> , 2017, 42, e253-e254. | 1.3 | 1 |
| 184 | Therapy monitoring with PET in cancer patients: achievements, opportunities and challenges ahead for the PET community. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1-3. | 6.4 | 3 |
| 185 | Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (¹⁸ F) PET/CT in Biochemically Recurrent Prostate Cancer. <i>Journal of Urology</i> , 2017, 197, 676-683. | 0.4 | 165 |
| 186 | Rationale for Modernising Imaging in Advanced Prostate Cancer. <i>European Urology Focus</i> , 2017, 3, 223-239. | 3.1 | 62 |
| 187 | Molecular Imaging and Precision Medicine in Prostate Cancer. <i>PET Clinics</i> , 2017, 12, 83-92. | 3.0 | 9 |
| 188 | The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 215-223. | 6.4 | 52 |
| 189 | ¹⁸ F-FDG PET-Guided External Beam Radiotherapy in Iodine-Refractory Differentiated Thyroid Cancer: A Pilot Study. <i>Journal of Thyroid Research</i> , 2017, 2017, 1-9. | 1.3 | 2 |
| 190 | New Radiopharmaceutical Markers for Metabolism and Receptor. , 2017, , 95-104. | | 0 |
| 191 | Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. , 2017, , 749-775. | | 0 |
| 192 | ¹⁸ F-Fdg-PET-guided Planning and Re-Planning (Adaptive) Radiotherapy in Head and Neck Cancer: Current State of Art. <i>Anticancer Research</i> , 2017, 37, 6523-6532. | 1.1 | 8 |
| 193 | Prognostic Evaluation of Disease Outcome in Solid Tumors Investigated With ⁶⁴ Cu-ATSM PET/CT. <i>Clinical Nuclear Medicine</i> , 2016, 41, e87-e92. | 1.3 | 32 |
| 194 | Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors. <i>Anti-Cancer Drugs</i> , 2016, 27, 353-363. | 1.4 | 5 |
| 195 | Reply to Egesta Lopci, Arturo Chiti, and Massimo Lazzeri's Letter to the Editor re: Laura Evangelista, Alberto Briganti, Stefano Fanti, et al. New Clinical Indications for ¹⁸ F/ ¹¹ C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. <i>Eur Urol</i> 2016;70:161-75. <i>European Urology</i> , 2016, 70, e114-e115. | 1.9 | 2 |
| 196 | Complete pathological response after chemo-radiation in anaplastic thyroid cancer: A report of two cases. <i>Acta Oncologica</i> , 2016, 55, 530-532. | 1.8 | 3 |
| 197 | ¹¹ C- or ¹⁸ F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 43S-48S. | 5.0 | 42 |
| 198 | Evaluation of Prostate Cancer with ¹¹ C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis. <i>Journal of Nuclear Medicine</i> , 2016, 57, 49S-54S. | 5.0 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs. <i>Journal of Nuclear Medicine</i> , 2016, 57, 61S-66S. | 5.0 | 35 |
| 200 | The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. <i>Lancet Haematology</i> , 2016, 3, e467-e479. | 4.6 | 63 |
| 201 | PET imaging in prostate cancer, state of the art: a review of 18F-choline and 11C-choline PET/CT applications. <i>Clinical and Translational Imaging</i> , 2016, 4, 449-456. | 2.1 | 1 |
| 202 | Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2122-2130. | 6.4 | 42 |
| 203 | Molecular imaging and prostate cancer: unmet clinical needs and future perspectives. <i>Clinical and Translational Imaging</i> , 2016, 4, 421-422. | 2.1 | 2 |
| 204 | PET Tracers Beyond FDG in Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 507-521. | 4.6 | 62 |
| 205 | PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2103-2104. | 6.4 | 7 |
| 206 | Of standard of reference and accuracy: the problem of truth in imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 52-54. | 6.4 | 6 |
| 207 | 11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1971-1979. | 6.4 | 79 |
| 208 | 11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 84-91. | 6.4 | 77 |
| 209 | Unusual Thyroid Carcinoma Metastases: a Case Series and Literature Review. <i>Endocrine Pathology</i> , 2016, 27, 55-64. | 9.0 | 52 |
| 210 | The Possible Role of PET Imaging Toward Individualized Management of Bone and Soft Tissue Malignancies. <i>PET Clinics</i> , 2016, 11, 285-296. | 3.0 | 7 |
| 211 | New Clinical Indications for 18 F/ 11 C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. <i>European Urology</i> , 2016, 70, 161-175. | 1.9 | 184 |
| 212 | 18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1601-1610. | 6.4 | 204 |
| 213 | Imaging for Prostate Cancer Recurrence. <i>European Urology Focus</i> , 2016, 2, 139-150. | 3.1 | 36 |
| 214 | Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET Use). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 414-421. | 6.4 | 92 |
| 215 | PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 55-69. | 6.4 | 200 |
| 216 | Pleuroparenchymal fibroelastosis: the prevalence of secondary forms in hematopoietic stem cell and lung transplantation recipients. <i>Diagnostic and Interventional Radiology</i> , 2016, 22, 400-406. | 1.5 | 61 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | 18F-FDG PET/CT for Bone and Soft Tissue Biopsy. , 2016, , 87-93. | | 0 |
| 218 | Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial. Blood, 2016, 128, 992-992. | 1.4 | 0 |
| 219 | 11C-Meta-Hydroxyephedrine. Clinical Nuclear Medicine, 2015, 40, e96-e103. | 1.3 | 14 |
| 220 | 68Ga DOTANOC PET/CT Detects Primary Malignant Insulinoma. Clinical Nuclear Medicine, 2015, 40, e132-e133. | 1.3 | 9 |
| 221 | 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse. Clinical Nuclear Medicine, 2015, 40, e386-e391. | 1.3 | 118 |
| 222 | Multicenter study evaluating extraprostatic uptake of 11C-choline, 18F-methylcholine, and 18F-ethylcholine in male patients. Nuclear Medicine Communications, 2015, 36, 1065-1075. | 1.1 | 25 |
| 223 | 11C-Choline PET/CT Identifies Osteoblastic and Osteolytic Lesions in Patients with Metastatic Prostate Cancer. Clinical Nuclear Medicine, 2015, 40, e265-e270. | 1.3 | 39 |
| 224 | Cardiac resynchronization therapy and cardiac sympathetic function. European Journal of Clinical Investigation, 2015, 45, 792-799. | 3.4 | 18 |
| 225 | Engineered porphyrin loaded core-shell nanoparticles for selective sonodynamic anticancer treatment. Nanomedicine, 2015, 10, 3483-3494. | 3.3 | 57 |
| 226 | Prognostic Value of ⁶⁸ Ga-DOTANOC PET/CT SUV _{max} in Patients with Neuroendocrine Tumors of the Pancreas. Journal of Nuclear Medicine, 2015, 56, 1843-1848. | 5.0 | 78 |
| 227 | Reply: Critical Views on the Prognostic Potential and Interpretation of Bone Marrow ¹⁸ F-FDG PET in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine, 2015, 56, 164-164. | 5.0 | 3 |
| 228 | PET in natural killer/T-cell lymphoma: the debate continues. Lancet Haematology, the, 2015, 2, e50-e51. | 4.6 | 0 |
| 229 | Identifying sites of recurrence with choline-PET-CT imaging. Nature Reviews Urology, 2015, 12, 134-135. | 3.8 | 9 |
| 230 | Prospective Comparison of ¹⁸ F-Fluoromethylcholine Versus ⁶⁸ Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. Journal of Nuclear Medicine, 2015, 56, 1185-1190. | 5.0 | 516 |
| 231 | FDG PET/CT for bone and soft-tissue biopsy. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1333-1334. | 6.4 | 10 |
| 232 | 68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1284-1294. | 6.4 | 234 |
| 233 | 11C-Choline PET/CT and Bladder Cancer. Clinical Nuclear Medicine, 2015, 40, e124-e128. | 1.3 | 30 |
| 234 | 11C-Choline PET/CT for Restaging of Bladder Cancer. Clinical Nuclear Medicine, 2015, 40, e1-e5. | 1.3 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 4384-4390. | 7.0 | 140 |
| 236 | ⁶⁸ Ga-PSMA-PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse After Radical Prostatectomy for Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e415-e417. | 1.9 | 15 |
| 237 | PET/Computed Tomography in the Individualization of Treatment of Prostate Cancer. <i>PET Clinics</i> , 2015, 10, 487-494. | 3.0 | 5 |
| 238 | Heterogeneous response of cardiac sympathetic function to cardiac resynchronization therapy in heart failure documented by ¹¹ C]-hydroxy-ephedrine and PET/CT. <i>Nuclear Medicine and Biology</i> , 2015, 42, 858-863. | 0.6 | 11 |
| 239 | The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients. <i>Hematological Oncology</i> , 2015, 33, 145-150. | 1.7 | 30 |
| 240 | ¹⁸ F-Fluorothymidine Positron Emission Tomography in Patients with Suspect Lymphoma Relapse. <i>Blood</i> , 2015, 126, 5009-5009. | 1.4 | 0 |
| 241 | State of the art of PET/CT with ¹¹ C-choline and ¹⁸ F-fluorocholine in the diagnosis and follow-up of localized and locally advanced prostate cancer. <i>Archivos Espanoles De Urologia</i> , 2015, 68, 354-70. | 0.2 | 14 |
| 242 | First case of ¹⁸ F-FACBC PET/CT-guided salvage radiotherapy for local relapse after radical prostatectomy with negative ¹¹ C-Choline PET/CT and multiparametric MRI: New imaging techniques may improve patient selection. <i>Archivio Italiano Di Urologia Andrologia</i> , 2014, 86, 239. | 0.8 | 8 |
| 243 | Sulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAIL-sensitivity in the aggressive alveolar subtype leading to tumor elimination in mice. <i>Cancer Biology and Therapy</i> , 2014, 15, 1219-1225. | 3.4 | 21 |
| 244 | Impact of ¹¹ C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2222-2231. | 6.4 | 86 |
| 245 | Prospective International Cohort Study Demonstrates Inability of Interim PET to Predict Treatment Failure in Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1936-1944. | 5.0 | 63 |
| 246 | Anti-1-Amino-3- ¹⁸ F-Fluorocyclobutane-1-Carboxylic Acid: Physiologic Uptake Patterns, Incidental Findings, and Variants That May Simulate Disease. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1986-1992. | 5.0 | 138 |
| 247 | Nuclear medicine in urological cancers: what is new?. <i>Future Oncology</i> , 2014, 10, 2061-2072. | 2.4 | 3 |
| 248 | Diagnostic Accuracy of ¹¹ C-Choline PET/CT in Preoperative Lymph Node Staging of Bladder Cancer. <i>Clinical Nuclear Medicine</i> , 2014, 39, e308-e312. | 1.3 | 39 |
| 249 | Pretherapeutic Dosimetry in Patients Affected by Metastatic Thyroid Cancer Using ¹²⁴ I PET/CT Sequential Scans for ¹³¹ I Treatment Planning. <i>Clinical Nuclear Medicine</i> , 2014, 39, e367-e374. | 1.3 | 28 |
| 250 | Restaging Clear Cell Renal Carcinoma With ¹⁸ F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2014, 39, e320-e324. | 1.3 | 32 |
| 251 | Usefulness of ⁶⁴ Cu-ATSM in Head and Neck Cancer. <i>Clinical Nuclear Medicine</i> , 2014, 39, e59-e63. | 1.3 | 36 |
| 252 | First Case of ¹⁸ F-FACBC PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse after Radical Prostatectomy for Prostate Cancer and Negative ¹¹ C-Choline PET/CT: New Imaging Techniques May Expand Pioneering Approaches. <i>Urologia Internationalis</i> , 2014, 92, 242-245. | 1.3 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | The Use of Gallium-68 Labeled Somatostatin Receptors in PET/CT Imaging. <i>PET Clinics</i> , 2014, 9, 323-329. | 3.0 | 45 |
| 254 | ¹¹ C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 878-886. | 6.4 | 54 |
| 255 | ¹⁸ F-FDG PET/CT impact on testicular tumours clinical management. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 668-673. | 6.4 | 60 |
| 256 | Is the detection rate of ¹⁸ F-choline PET/CT influenced by androgen-deprivation therapy?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1293-1300. | 6.4 | 25 |
| 257 | Prognostic value of ¹⁸ F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1046-1056. | 6.4 | 49 |
| 258 | FDG PET/CT in autoimmune pancreatitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1264-1265. | 6.4 | 5 |
| 259 | Combined computed tomography and fluorodeoxyglucose positron emission tomography in the diagnosis of prosthetic valve endocarditis: a case series. <i>BMC Research Notes</i> , 2014, 7, 32. | 1.4 | 32 |
| 260 | ⁶⁸ Ga-DOTA-peptides in the Diagnosis of NET. <i>PET Clinics</i> , 2014, 9, 37-42. | 3.0 | 32 |
| 261 | Role of ¹⁸ F-FDG PET/CT in the diagnosis of infective endocarditis in patients with an implanted cardiac device: a prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1617-1623. | 6.4 | 79 |
| 262 | FDG and other radiopharmaceuticals in the evaluation of liver lesions. <i>Clinical and Translational Imaging</i> , 2014, 2, 115-127. | 2.1 | 2 |
| 263 | Radiopharmaceuticals in the evaluation and treatment of liver lesions. <i>Clinical and Translational Imaging</i> , 2014, 2, 99-101. | 2.1 | 0 |
| 264 | Combined PET and Biopsy Evidence of Marrow Involvement Improves Prognostic Prediction in Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1591-1597. | 5.0 | 62 |
| 265 | Imaging the Folate Receptor on Cancer Cells with ^{99m} Tc-Etarfolatide: Properties, Clinical Use, and Future Potential of Folate Receptor Imaging. <i>Journal of Nuclear Medicine</i> , 2014, 55, 701-704. | 5.0 | 59 |
| 266 | Early Biochemical Relapse After Radical Prostatectomy: Which Prostate Cancer Patients May Benefit from a Restaging ¹¹ C-Choline PET/CT Scan Before Salvage Radiation Therapy?. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1424-1429. | 5.0 | 118 |
| 267 | Performance of FDG PET/ceCT in the evaluation of patients with lung cancer. <i>Biomedicine and Pharmacotherapy</i> , 2014, 68, 219-223. | 5.6 | 4 |
| 268 | ¹⁸ F-FACBC Compared With ¹¹ C-Choline PET/CT in Patients With Biochemical Relapse After Radical Prostatectomy: A Prospective Study in 28 Patients. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 106-110. | 1.9 | 68 |
| 269 | Positron Emission Tomography With Computed Tomography-Based Diagnosis of Massive Extramedullary Progression in a Patient With High-Risk Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e101-e104. | 0.4 | 10 |
| 270 | Diagnostic accuracy of FDG PET/CT in mediastinal lymph nodes from lung cancer. <i>European Journal of Radiology</i> , 2014, 83, 1301-1302. | 2.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | Incidentally Detected Increased FDG Uptake in Bowel and its Correlation with Hystopathological Data: Our Experience in a Case Series Study. <i>Current Radiopharmaceuticals</i> , 2014, 7, 107-114. | 0.8 | 3 |
| 272 | ¹¹ C-mHED for PET / CT: Principles of Synthesis, Methodology and First Clinical Applications. <i>Current Radiopharmaceuticals</i> , 2014, 7, 79-83. | 0.8 | 5 |
| 273 | PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 365-84. | 1.0 | 109 |
| 274 | 18F-FDG PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with suspected cardiac endocarditis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1190-1196. | 6.4 | 63 |
| 275 | Cardiac FDG PET/CT is useful to assess the culprit lesion in nonST-segment elevation myocardial infarction (NSTEMI). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 642-643. | 6.4 | 0 |
| 276 | 11C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 149-155. | 6.4 | 49 |
| 277 | Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 11-17. | 6.4 | 109 |
| 278 | Molecular Imaging of Neuroblastoma Progression in TH-MYCN Transgenic Mice. <i>Molecular Imaging and Biology</i> , 2013, 15, 194-202. | 2.6 | 12 |
| 279 | 11C-meta-hydroxyephedrine PET/CT imaging allows in vivo study of adaptive thermogenesis and white-to-brown fat conversion. <i>Molecular Metabolism</i> , 2013, 2, 153-160. | 6.5 | 21 |
| 280 | Pulmonary artery intimal sarcoma. Problems in the differential diagnosis. <i>Radiologia Medica</i> , 2013, 118, 1259-1268. | 7.7 | 42 |
| 281 | Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1695-1701. | 2.0 | 9 |
| 282 | The additional diagnostic value of contemporary evaluation of FDG PET/CT scan and contrast enhanced CT imaging both acquired by a last generation PET/CT system in oncologic patients. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 172-178. | 5.6 | 10 |
| 283 | The detection of disease relapse after radical treatment for prostate cancer. <i>Nuclear Medicine Communications</i> , 2013, 34, 831-833. | 1.1 | 13 |
| 284 | 11C-Choline PET/CT Scan in Patients With Prostate Cancer Treated With Intermittent ADT. <i>Clinical Nuclear Medicine</i> , 2013, 38, e279-e282. | 1.3 | 14 |
| 285 | The Role of 11C-Choline PET Imaging in the Early Detection of Recurrence in Surgically Treated Prostate Cancer Patients With Very Low PSA Level ≤ 0.5 ng/mL. <i>Clinical Nuclear Medicine</i> , 2013, 38, e342-e345. | 1.3 | 63 |
| 286 | Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. <i>Hematological Oncology</i> , 2013, 31, 183-188. | 1.7 | 27 |
| 287 | PET/CT in the Management and Prognosis of Pancreatic Exocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2013, 38, 33-34. | 1.3 | 1 |
| 288 | The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM). <i>Clinical Nuclear Medicine</i> , 2013, 38, e74-e79. | 1.3 | 65 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | 18F-FDG PET/CT for the Assessment of Disease Extension and Activity in Patients With Sarcoidosis. <i>Clinical Nuclear Medicine</i> , 2013, 38, e171-e177. | 1.3 | 66 |
| 290 | Sequential R-CHOP and R-FM Chemotherapy Followed By Autologous Stem Cell Transplantation Results In High Rates Of Long Term Remission In Advanced Follicular Lymphoma. <i>Blood</i> , 2013, 122, 5543-5543. | 1.4 | 0 |
| 291 | Antitumor Activity of Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigene Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 796-807. | 7.0 | 74 |
| 292 | Feasibility of Carbidopa Premedication in Pediatric Patients: A Pilot Study. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 729-733. | 1.0 | 11 |
| 293 | 18F-DOPA PET/CT in Neuroblastoma. <i>Clinical Nuclear Medicine</i> , 2012, 37, e73-e78. | 1.3 | 63 |
| 294 | PET/CT imaging in different types of lung cancer: An overview. <i>European Journal of Radiology</i> , 2012, 81, 988-1001. | 2.6 | 132 |
| 295 | Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. <i>European Journal of Radiology</i> , 2012, 81, e893-e896. | 2.6 | 106 |
| 296 | GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers. <i>BMC Cancer</i> , 2012, 12, 586. | 2.6 | 24 |
| 297 | FDG PET/CT is useful for the interim evaluation of response to therapy in patients affected by haematogenous spondylodiscitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1538-1544. | 6.4 | 76 |
| 298 | 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 52-60. | 6.4 | 112 |
| 299 | Is 68Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1278-1283. | 6.4 | 34 |
| 300 | Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 57-71. | 6.4 | 111 |
| 301 | Collection of Hematopoietic Stem Cells After Previous Exposure to Itrium-90 Ibritumumab Tiuxetan (Zevalin) Is Feasible and Does Not Impair Autologous Stem Cell Transplantation Outcome in Follicular Lymphoma.. <i>Blood</i> , 2012, 120, 3019-3019. | 1.4 | 5 |
| 302 | Choline PET/CT for prostate cancer: Main clinical applications. <i>European Journal of Radiology</i> , 2011, 80, e50-e56. | 2.6 | 55 |
| 303 | Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. <i>Blood</i> , 2011, 118, 5989-5995. | 1.4 | 445 |
| 304 | The Role of Choline Positron Emission Tomography/Computed Tomography in the Management of Patients with Prostate-Specific Antigen Progression After Radical Treatment of Prostate Cancer. <i>European Urology</i> , 2011, 59, 51-60. | 1.9 | 177 |
| 305 | Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase < 1.5Ång/ml?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 55-63. | 6.4 | 166 |
| 306 | 18F-FDG PET/CT detects systemic involvement in sarcoidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 2102-2102. | 6.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 307 | Androgen deprivation therapy influences the uptake of ¹¹ C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1985-1989. | 6.4 | 67 |
| 308 | Midtreatment ¹⁸ F-Fluorodeoxyglucose positron emission tomography in aggressive non-Hodgkin lymphoma. <i>Cancer</i> , 2011, 117, 1010-1018. | 4.1 | 60 |
| 309 | Incidence of Increased ⁶⁸ Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CT. <i>Journal of Nuclear Medicine</i> , 2011, 52, 886-890. | 5.0 | 57 |
| 310 | Detection of unknown primary neuroendocrine tumours (CUP-NET) using ⁶⁸ Ga-DOTA-NOC receptor PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 67-77. | 6.4 | 229 |
| 311 | ⁶⁸ Ga-somatostatin analogues PET and ¹⁸ F-DOPA PET in medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 46-48. | 6.4 | 30 |
| 312 | ⁶⁸ Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 722-727. | 6.4 | 107 |
| 313 | Procedure guidelines for PET/CT tumour imaging with ⁶⁸ Ga-DOTA-conjugated peptides: ⁶⁸ Ga-DOTA-TOC, ⁶⁸ Ga-DOTA-NOC, ⁶⁸ Ga-DOTA-TATE. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2004-2010. | 6.4 | 394 |
| 314 | Role of ¹¹ C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. <i>Annals of Nuclear Medicine</i> , 2010, 24, 485-492. | 2.2 | 70 |
| 315 | Standardized Uptake Values of ⁶⁸ Ga-DOTANOC PET: A Promising Prognostic Tool in Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2010, 51, 353-359. | 5.0 | 161 |
| 316 | Phase II Trial of Short-Course R-Chop Followed by ⁹⁰ Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients. <i>Clinical Cancer Research</i> , 2010, 16, 3998-4004. | 7.0 | 60 |
| 317 | ⁶⁸ Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2010, 51, 669-673. | 5.0 | 227 |
| 318 | ¹¹ C-Acetate PET for Early Prediction of Sunitinib Response in Metastatic Renal Cell Carcinoma. <i>Tumori</i> , 2009, 95, 382-384. | 1.1 | 28 |
| 319 | Influence of Trigger PSA and PSA Kinetics on ¹¹ C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1394-1400. | 5.0 | 230 |
| 320 | C-11 Acetate Does Not Enhance Usefulness of F-18 FDG PET/CT in Differentiating Between Focal Nodular Hyperplasia and Hepatic Adenoma. <i>Clinical Nuclear Medicine</i> , 2009, 34, 659-665. | 1.3 | 21 |
| 321 | ⁶⁸ Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. <i>Nuclear Medicine Communications</i> , 2009, 30, 281-286. | 1.1 | 89 |
| 322 | Predictive role of Early Interim FDG-PET in Hodgkin Lymphoma.. <i>Blood</i> , 2009, 114, 1659-1659. | 1.4 | 2 |
| 323 | A Phase II Trial of R-FM (Rituximab, Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (⁹⁰ Y) Ibritumomab Tiuxetan (⁹⁰ Y-IT) for Untreated Follicular Lymphoma (FL) Patients.. <i>Blood</i> , 2009, 114, 3743-3743. | 1.4 | 1 |
| 324 | A Phase II Trial of Rituximab-CHOP Chemotherapy Followed by Yttrium 90 (⁹⁰ Y) Ibritumomab Tiuxetan (⁹⁰ Y-IT) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.. <i>Blood</i> , 2009, 114, 2720-2720. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 325 | Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1431-1438. | 6.4 | 254 |
| 326 | 11C-Choline Positron Emission Tomography/Computerized Tomography for Preoperative Lymph-Node Staging in Intermediate-Risk and High-Risk Prostate Cancer: Comparison with Clinical Staging Nomograms. <i>European Urology</i> , 2008, 54, 392-401. | 1.9 | 232 |
| 327 | Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. <i>Biomedicine and Pharmacotherapy</i> , 2008, 62, 667-671. | 5.6 | 82 |
| 328 | Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). <i>Lancet Oncology</i> , The, 2008, 9, 352-358. | 10.7 | 80 |
| 329 | PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and Metabolism. <i>PET Clinics</i> , 2008, 3, 355-379. | 3.0 | 5 |
| 330 | ITF2357, a Novel Histone-Deacetylase Inhibitor, Is Effective against Peripheral T-Cell Lymphomas in Vivo. <i>Blood</i> , 2008, 112, 4981-4981. | 1.4 | 5 |
| 331 | A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. <i>Haematologica</i> , 2007, 92, 50-55. | 3.5 | 318 |
| 332 | Prostate Cancer: Sextant Localization with MR Imaging, MR Spectroscopy, and ¹¹ C-Choline PET/CT. <i>Radiology</i> , 2007, 244, 797-806. | 7.3 | 193 |
| 333 | PET/CT in Neuroendocrine Tumors: Evaluation of Receptor Status and Metabolism. <i>PET Clinics</i> , 2007, 2, 351-375. | 3.0 | 10 |
| 334 | Adrenocortical Positron Emission Tomography/PET-CT Imaging. <i>PET Clinics</i> , 2007, 2, 331-339. | 3.0 | 3 |
| 335 | Epithelial and Mesenchymal Tumor Compartments Exhibit In Vivo Complementary Patterns of Vascular Perfusion and Glucose Metabolism. <i>Neoplasia</i> , 2007, 9, 900-908. | 5.3 | 24 |
| 336 | Preface. <i>PET Clinics</i> , 2007, 2, xi-xiii. | 3.0 | 1 |
| 337 | 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. <i>World Journal of Surgical Oncology</i> , 2007, 5, 68. | 1.9 | 97 |
| 338 | FDG small animal PET permits early detection of malignant cells in a xenograft murine model. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 755-762. | 6.4 | 25 |
| 339 | 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 2096-2101. | 1.3 | 54 |
| 340 | Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 525-531. | 6.4 | 135 |
| 341 | Role of 18f-FDG PET/CT in the Management of Multiple Myeloma.. <i>Blood</i> , 2005, 106, 3492-3492. | 1.4 | 0 |
| 342 | Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1642-9. | 5.0 | 178 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 343 | Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 1396-1403. | 6.4 | 143 |